Prevention Of Recurrence Of Atrial Fibrillation

The purpose of this study is to determine whether the study drug is effective in preventing the recurrence of atrial fibrillation (an abnormal heart rhythm).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Fibrillation, Atrial Arrhythmias, Cardiac Atrial Fibrillation Cardiovascular Diseases Heart Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Symptomatic persistent atrial fibrillation requiring DC cardioversion.
Duration of AF >48 hrs. <6 months

Exclusion criteria

Concomitant Class I and/or III anti-arrhythmic drugs.
Amiodarone treatment within 3 months of the study.
Other inclusion or exclusion criteria to be determined by the physician and study sponsor.

Treatment and study plan

SB-207266

Drug

White, oval, biconvex tablets containing either 10mg, 25mg or 40mg

Placebo

Other

Placebo to match SB-207266

Primary outcomes

Time-to-first symptomatic AF (atrial fibrillation)

Time frame: Up to 26 Weeks

Secondary outcomes

Time to first symptomatic or detected asymptomatic AF; spontaneous reversion to sinus rhythm prior to cardioversion

Time frame: Up to 26 Weeks

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Safety and Efficacy of SB 207266 in Patients With Symptomatic Persistent Atrial Fibrillation (AF)

Important dates

Study start: 2001
Primary completion: 2003
Study completion: 2003
First posted: Jul 12, 2002
Registry last updated: Aug 11, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed